Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Brentuximab vedotin plus CHP-like versus CHOEP regimen for the first-line treatment of PTCL patients: a multi-center propensity-matched retrospective study

The optimal frontline treatment option for Peripheral T-cell lymphomas (PTCLs) has not been completely defined. To compare the efficacy and safety of brentuximab vedotin (BV) combined with CHP-like regimen (cyclophosphamide, an anthracycline component, and prednisone) and CHOEP regimen (cyclophosphamide, dox...

Jing Chen, F. Guan, Zhi-Peng Cheng et al. · 0 citations
Open access Oct 2026

Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma.

Data on long-term outcomes of in vivo chimeric antigen receptor T cell (CAR‑T) therapy remain scarce. We previously reported preliminary safety and efficacy data of in vivo B-cell maturation antigen (BCMA) CAR‑T (ESO-T01), in four patients with relapsed/refractory multiple myeloma, without leukapheresis and lymphodeple...

Jia Xu, Lin Liu, Wei Xie et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.